Literature DB >> 17083308

Can we define the ideal duration of antibiotic therapy?

Traci L Hedrick1, Heather L Evans, Robert L Smith, Shannon T McElearney, Alison S Schulman, Tae W Chong, Timothy L Pruett, Robert G Sawyer.   

Abstract

BACKGROUND: Because of the increasing development of antimicrobial resistance, there is a greater responsibility within the medical community to limit the exposure of patients to antibiotics. We tested the hypothesis that shorter courses of antibiotics are associated with similar or better results than longer durations. We also sought to investigate the difference between a fixed duration of therapy and one based on physiologic measures such as fever and leukocytosis.
METHODS: All infectious episodes on the general surgery units of the University of Virginia Health System from December 15, 1996, to July 31, 2003, were analyzed retrospectively for the relation between the duration of antibiotic therapy and infectious complications (recurrent infection with the same organism or at the same site). All infections associated with either fever or leukocytosis were categorized into quartiles on the basis of the absolute length of antibiotic administration or the duration of treatment following resolution of fever or leukocytosis. Multivariate logistic regression models were developed to estimate the independent risk of recurrence associated with a longer duration of antibiotic use.
RESULTS: Of the 5,561 treated infections, 4,470 were associated with fever (temperature > or =38 degrees C) or leukocytosis (white blood cell count > or =11,000/mm(3)). For all infections, whether analyzed by absolute duration or time from resolution of leukocytosis or fever, the first or second quartiles (0-12 days, 0-9 days, 0-9 days, respectively) were associated with the lowest recurrence rates (14-18%, 17-23%, 18-19%, respectively). Individual analysis of intra-abdominal infections and pneumonia yielded similar results. The fixed-duration groups received fewer days of antibiotics on average, with outcomes similar to those in the physiologic parameters group.
CONCLUSIONS: Shorter courses of antibiotics were associated with similar or fewer complications than prolonged therapy. In general, adopting a strategy of a fixed duration of therapy, rather than basing duration on resolution of fever or leukocytosis, appeared to yield similar outcomes with less antibiotic use.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17083308     DOI: 10.1089/sur.2006.7.419

Source DB:  PubMed          Journal:  Surg Infect (Larchmt)        ISSN: 1096-2964            Impact factor:   2.150


  12 in total

Review 1.  Complicated Intra-Abdominal Infections: The Old Antimicrobials and the New Players.

Authors:  Young R Lee; Danni McMahan; Catherine McCall; Gregory K Perry
Journal:  Drugs       Date:  2015-12       Impact factor: 9.546

2.  Metabolic support of the enterocutaneous fistula patient.

Authors:  Joshua I S Bleier; Traci Hedrick
Journal:  Clin Colon Rectal Surg       Date:  2010-09

3.  Audit of antibiotic duration of therapy, appropriateness and outcome in patients with nosocomial pneumonia following the removal of an automatic stop-date policy.

Authors:  J Do; S A N Walker; S E Walker; W Cornish; A E Simor
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-01-11       Impact factor: 3.267

4.  Association of excessive duration of antibiotic therapy for intra-abdominal infection with subsequent extra-abdominal infection and death: a study of 2,552 consecutive infections.

Authors:  Lin M Riccio; Kimberley A Popovsky; Tjasa Hranjec; Amani D Politano; Laura H Rosenberger; Kristin C Tura; Robert G Sawyer
Journal:  Surg Infect (Larchmt)       Date:  2014-05-13       Impact factor: 2.150

5.  Aggressive versus conservative initiation of antimicrobial treatment in critically ill surgical patients with suspected intensive-care-unit-acquired infection: a quasi-experimental, before and after observational cohort study.

Authors:  Tjasa Hranjec; Laura H Rosenberger; Brian Swenson; Rosemarie Metzger; Tanya R Flohr; Amani D Politano; Lin M Riccio; Kimberley A Popovsky; Robert G Sawyer
Journal:  Lancet Infect Dis       Date:  2012-08-28       Impact factor: 25.071

6.  2013 WSES guidelines for management of intra-abdominal infections.

Authors:  Massimo Sartelli; Pierluigi Viale; Fausto Catena; Luca Ansaloni; Ernest Moore; Mark Malangoni; Frederick A Moore; George Velmahos; Raul Coimbra; Rao Ivatury; Andrew Peitzman; Kaoru Koike; Ari Leppaniemi; Walter Biffl; Clay Cothren Burlew; Zsolt J Balogh; Ken Boffard; Cino Bendinelli; Sanjay Gupta; Yoram Kluger; Ferdinando Agresta; Salomone Di Saverio; Imtiaz Wani; Alex Escalona; Carlos Ordonez; Gustavo P Fraga; Gerson Alves Pereira Junior; Miklosh Bala; Yunfeng Cui; Sanjay Marwah; Boris Sakakushev; Victor Kong; Noel Naidoo; Adamu Ahmed; Ashraf Abbas; Gianluca Guercioni; Nereo Vettoretto; Rafael Díaz-Nieto; Ihor Gerych; Cristian Tranà; Mario Paulo Faro; Kuo-Ching Yuan; Kenneth Yuh Yen Kok; Alain Chichom Mefire; Jae Gil Lee; Suk-Kyung Hong; Wagih Ghnnam; Boonying Siribumrungwong; Norio Sato; Kiyoshi Murata; Takayuki Irahara; Federico Coccolini; Helmut A Segovia Lohse; Alfredo Verni; Tomohisa Shoko
Journal:  World J Emerg Surg       Date:  2013-01-08       Impact factor: 5.469

7.  A Comprehensive review of abdominal infections.

Authors:  Nicole Lopez; Leslie Kobayashi; Raul Coimbra
Journal:  World J Emerg Surg       Date:  2011-02-23       Impact factor: 5.469

Review 8.  Duration of antibiotic therapy for bacteremia: a systematic review and meta-analysis.

Authors:  Thomas C Havey; Robert A Fowler; Nick Daneman
Journal:  Crit Care       Date:  2011-11-15       Impact factor: 9.097

Review 9.  Antimicrobial Stewardship Programs: Appropriate Measures and Metrics to Study their Impact.

Authors:  Andrew M Morris
Journal:  Curr Treat Options Infect Dis       Date:  2014

10.  CT findings and features of postoperative abdominal infection patients with pancreatic carcinoma.

Authors:  Yuzhuo Ma; Guangsheng Liu; Lingling Zhang
Journal:  Pak J Med Sci       Date:  2017 May-Jun       Impact factor: 1.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.